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1. Introduction   
In October 1999, the Food and Drug Administration (USA) approved a health claim for soy 
indicating that consumption of 25 grams of soy protein a day as part of a diet low in 
saturated fats and cholesterol may help lower the risk of heart disease.  Additionally, soy 
has officially been approved in the UK, Brazil, Malaysia, Japan, Korea, Philippines, 
Indonesia and South Africa.   
Some countries have, however, been slower to approve a health claim and are requiring 
more substantive evidence. Questions of concern include the impact of processing on the 
efficacity of soy protein,  information on the normal and acceptable levels of isoflavones in 
soy products, efficacy of soy proteins in which isoflavones have been removed versus soy 
proteins containing isoflavones in respect to  relationship with cardiovascular disease risk 
reduction, feasibility of consumers to take in 25 g of soy protein a day, effect of 
antinutritional factors (e.g., trypsin inhibitors, phytates, lectins, lysinoalanine), heat 
resistance of trypsin inhibitors found in soybeans and the specific effects of soy protein 
alone compared to soy protein within a matrix (e.g., whole soybean foods and foods made 
from soy protein ingredients).   
These questions are pertinent as there is a wide variety of soyfoods available on the market 
with different macro and micro nutrient compositions. Answers to these questions will 
therefore be useful in identifying the specific conditions required for soyfoods to carry a 
health claim. 
Foods prepared from whole soybeans include soymilk and tofu. Soybean derived 
ingredients include defatted soy flour, soy protein concentrate, soy protein isolate and soy 
fibre. Soy protein isolates in particular have been very successful commercially and are used 
extensively today in the production of a large number of foods. Different techniques can be 
used for making soy protein isolate and the type of processing treatment used can affect the 
nutrient and physicochemical composition of the isolate (e.g., composition of residual 
isoflavones, saponins, trypsin inhibitors, phytic acid and minerals). Isoflavones, saponins, 
trypsin inhibitors and phytic acid are all biologically active molecules and as such variations 
in their composition can hinder the ability to determine if a reported health benefit is due to 
the soy protein alone or the presence of these other compounds.  
The chapter will provide a brief update on some of the reported health benefits of soy 
components. An overview of some of the major soyfoods and soy ingredients currently 
www.intechopen.com
 
Soybean and Nutrition 
 
454 
available on the market will be provided along with a detailed list comparing the effects of 
processing on the composition of different soy products. Requirements for obtaining health 
claims using the Canadian example, as well as impacts of compositional differences on 
potential health benefits are further presented.  
2. Soybeans and health 
Cardiovascular disease (CVD) is one of the leading causes of death in the world today. 
According to the World Health Organization by 2030, almost 23.6 million people will die 
from CVDs, mainly from heart disease and stroke (www.who.int/mediacentre).  Elevated 
low density lipoprotein (LDL) is a major cardiovascular disease risk factor. LDL transports 
cholesterol and triglycerides from the liver to peripheral tissues and arteries and regulates 
cholesterol synthesis. Retention of cholesterol in arteries can result in the formation of 
arterial plaques which increases the risk of atherosclerosis, peripheral vascular disease, 
strokes and heart attacks.  Foods that decrease LDL levels will, therefore, increasingly be of 
interest as health foods.  Several reports have shown a decrease in LDL levels and an 
increase in HDL after consumption of soy (Nilavsen & Meinertz, 1998; Potter et al., 1998; 
Merritt, 2004; Zhuo et al., 2004; Sacks et al., 2006; Harlanda & Haffnerb, 2008; Taku et al., 
2008). Earlier studies showing similar results formed the basis of the current soy health 
claim in many jurisdictions.  
Due to apparent inconsistencies in findings, in 2008 the Weston Price Foundation submitted 
a petition to the FDA in response to the FDA's request for public comment on the issue 
claiming that soy protein products are not safe and have no long history of use in the food 
supply. The organization also claimed the evidence on soy protein and heart disease was 
contradictory and inconsistent, and that no standard of scientific agreement had been met 
(http://www.physorg.com/news122663958.html).  
A systematic study conducted by the US department of Health & Human Services indicated 
that while the evidence was weak for other disease outcomes, there is a suggestion of a 
possible dose-response effect for soy protein for LDL reduction (http://www.ahrq.gov/ 
Clinic/epcsums/soysum.htm). 
Using predictive equations along with a meta-analysis to determine whether the heart 
health claim for soy continues to be justified, Jenkins et al. (2010) concluded that low density 
lipoprotein cholesterol (LDL-C) reduction attributable to the combined intrinsic and 
extrinsic effects of soy protein foods ranged from 7.9 to 10.3%. They further concluded from 
their study that soy remains one of a few food components that reduces serum cholesterol 
(>4%) when added to the diet. 
In a more recent study, Onuegbu et al. (2011) fed 500 mL of soymilk daily to 42 apparently 
healthy young to middle-aged subjects for a period of 21 days and reported that soymilk 
consumption significantly reduced mean plasma TC by 11% and LDL-C by 25% and 
increased mean plasma HDL-C by 20%. The authors also concluded that soy drink could be 
an important non-pharmacological cholesterol-reducing agent. 
Furthermore, Bruckert and Rosenbaum (2011) have also recently reported LDL-cholesterol 
reduction ranging from -3 to -10% for soy protein and have indicated that dietary 
recommendations may have important impacts on cardiovascular events as they can be 
implemented early in life and because the sum of the effect on LDL-cholesterol is far from 
being negligible.  
Another major risk factor for developing CVD is elevated blood pressure (EBP). A major 
contributor to EBP is Angiotensin II which is a potent vasoconstrictor. Vasoconstriction 
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occurs when renin, an enzyme produced in the kidneys, proteolytically acts on circulating 
angiotensinogen and converts it to angiotensin I (a decapeptide). In the presence of 
angiotensin converting enzyme (ACE), angiotensin I is cleaved to the octapeptide, 
angiotensin II resulting in arterial constriction and EBP. ACE also breaks down bradykinin, 
a vasodilator, further contributing to the elevation in blood pressure. Inhibition of ACE is, 
therefore, important for the lowering of blood pressure as this results in a decrease in the 
concentration of angiotensin II and an increase in the levels of bradykinin (Yang et al., 1970; 
Erdos, 1975). Various reports have suggested that peptides from soy posses ACE-inhibitory 
properties (Wu & Ding, 2002; Kuba et al., 2003; Chiang et al., 2006; Hartmann & Meisel, 
2007; Yang et al., 2008). These peptides are usually not active when present within the 
sequence of parent proteins, but are released by enzymatic proteolysis in vivo or in vitro.  
In addition to soy proteins, some reports have attributed the beneficial health effect of soy to 
phytochemicals found in soybeans such as isoflavones which are naturally occurring non-
steroid compounds with weak estrogenic effects and chemical structure similar to estradiol-
17 (Fig. 1). Isoflavones are able to bind to estrogen receptors and are capable of triggering 
estrogen dependent responses physiologically. The main types of isoflavones found in soy 
are the aglycones (daidzein, genistein, and glycitein), the β-glucosides (daidzin, genistin, 
and glycitin) and their 6″-O-malonyl-β-glucosides (6OMalGlc) and 6″-O-acetyl-β-glucosides 
(6OAcGlc) conjugates.  
Taku  et al. (2010) conducted a meta-analysis to clarify the effects of soy isoflavone extracts 
on systolic and diastolic blood pressure (SBP and DBP) in adult humans. They reported that 
soy isoflavone extracts significantly decreased SBP but not DBP in adult humans, however, 
no dose-response relationship was observed. 
 
OH
OH
Estradiol-17
(estrogen)
OHO
OH
OH
O
Soybean isoflavone
Genestein
(aglycone)
 
Fig. 1. Molecular  structure of soy isoflavone genistein compared to estradiol-17. 
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In other studies, high dietary intakes of soy isoflavones were found to be associated with 
lower risk of recurrence among postmenopausal patients with breast cancer positive for 
estrogen and progesterone receptor and those who were receiving anastrozole as endocrine 
therapy (Kang et al., 2010a, b) . 
Ogborn et al. (2010) have also recently reported that a soy diet ameliorated renal injury in 
rats. Soy diets preserved normal renal function and reduced relative renal weight, scores for 
cystic change, fibrosis, tissue oxidized LDL content, inflammation and epithelial cell 
proliferation. In this study though, alcohol-extracted slow isoflavone soy protein was found 
to retain its major protective effects and only subtle differences were attributed to 
isoflavones.  
Consumption of tofu containing high levels of isoflavones reportedly exerted positive effects 
on verbal memory, although not in older men and women, where no or negative effects of 
these compounds on brain cells and cognition was observed (Hogervorst et al., 2011). 
In regards to other health outcomes, Messina (2010) reported that although recent clinical 
data have not supported the skeletal benefits of isoflavones, 2 large prospective 
epidemiologic studies found soy intake to be associated with marked reductions in fracture 
risk. Additionally, soybean isoflavones modestly alleviate hot flashes in menopausal 
women. 
In addition to isoflavones, soy saponins may also exert bioactive effects. Orally administered 
commercial purified soy saponin at 80 mg/kg body weight/day to spontaneously 
hypertensive rats for 8 weeks significantly decreased blood pressure (Hiwatashi et al., 2010).  
In another study on the effect of soy saponins on the growth of human colon cancer cells, 
Tsai et al. (2010) reported that intake of soy saponin decreased the number of viable cells in 
a dose-dependent manner. They concluded that soy saponin may be effective in preventing 
colon cancer by affecting cell morphology, cell proliferation enzymes, and cell growth. 
Additionally, phytic acid which is considered to be an antinutritional component in soybean 
may possess antioxidant effects (Sakač et al., 2010).  Recent research studies further suggest 
that lunasin, lectins, and trypsin inhibitors may have beneficial health properties. Trypsin 
inhibitors in soy have been of particular concern  because, if not destroyed by heat prioir to 
consumption, they can cause pancreatic hypertrophy/hyperplasia, which ultimately results 
in growth inhibition (Liener, 1994,1996).  
The majority of approved health claim for soy covers only soy proteins as evidence 
surrounding the effects of isoflavones and other bioactive compouds in soy are more 
controversial. Overall, although many studies suggest that the beneficial properties of soy 
may be attributed to the protein fraction, questions remain about potential synergistic or 
complimentary effects of other soy components.  
In the sections below, an attempt will be made to provide a review of some of the different 
soy products available and their compositional differences and how this could impact their 
health properties. 
3. Commercially available soyfoods and ingredients 
Soybean has today become one of the world’s most economical and valuable agricultural 
commodities due to its unique composition. On a wet basis, soybeans contain about 35% 
protein, 17% oil, 31% carbohydrate and 4.4% ash. The composition varies for different 
varieties and some cultivars can be found with protein contents of up to 50%. Soy proteins 
are nutritionally superior among vegetable proteins. Soy protein isolate has a Protein 
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Digestibility Corrected Amino Acid Score (PDCAAS) of 100% which means that it has all the 
essential amino acids required to support growth and maintenance. It contains good 
supplies of essential amino acids, such as lysine, which are normally lacking in other cereals. 
Fatty acids in soybeans consist of unsaturated fats, such as oleic, linoleic and linolenic acids, 
which are nutritionally beneficial. Additionally, soybeans also contain  fibre and other 
phytochemicals, such as isoflavones and saponins which may have health benefits. 
3.1 Major soyfoods 
3.1.1 Soybeans and sprouts 
Green soybean and soybean sprouts are two whole soyfoods prepared from soybean seeds. 
Sprouts are obtained by germinating soybeans for 5-10 days. They may be consumed fresh 
(e.g., in salads) or used as a vegetable in cooking. Green vegetable soybean, on the other 
hand, is harvested just before maturity (edamame) and can be cooked and eaten in salads 
and in soups or as a snack. It is available fresh (in pod or shelled), canned or frozen. The 
composition of these two products although prepared from the whole seed will vary due to 
the germination process applied to sprouts. 
3.1.2 Soymilk 
Soymilk is the liquid extract obtained after cooking, grinding and filtering soybean. It is not 
a “whole soyfood” per se as the majority of the fibre fraction (okara) is removed during 
processing. The soymilk extract obtained after filtration has a consistency that is very similar 
to cow’s milk and is frequently used as an alternative to dairy products. There are four 
major types of soymilk products available (unsweetened, sweetened, flavoured and low fat). 
Unsweetened soymilk generally contains only water and soybeans. Sweetened soymilk may 
be sweetened with rice syrup, honey, corn or barley malt extract. Flavoured soymilk may be 
sweetened or unsweetened, and is often flavoured with cocoa, vanilla, carob or strawberry. 
Low fat soymilk may also be sweetened or unsweetened, flavoured or unflavoured, but 
usually contains less fat. Soymilk is frequently fortified with vitamins and minerals to 
increase its nutrient value. Blends of soymilk made with soybeans and different cereals or 
fruits are also available as well as “functional soymilk products” (e.g., with added omega 3 
or other functional ingredients). Some manufacturers process soymilk using soy protein 
isolate rather than starting with the bean.  
3.1.3 Tofu 
Tofu is a curd made from heated soymilk. It is prepared by adding coagulating agents such 
as glucono--lactone (GDL) or salts (magnesium chloride, calcium chloride, calcium 
sulphate) to heated soymilk followed by pressing to remove the whey. The final product is a 
gel with different textures and degrees of hardness depending on the type and amount of 
coagulant used and processing method (Fig.2). As with soymilk, tofu is not a “whole food” 
as the fibre is removed in the process of making the soymilk. The composition is also 
different from the starting soymilk as much of the whey is removed to concentrate the 
proteins and facilitate gel formation during pressing. Tofu has a soft white texture which is 
in some respects similar to cheese. On a wet basis, pressed tofu with a moisture content of 
about 85% contains 7.8% protein, 4.2% lipid, and 2 mg/g calcium (Wang et al., 1983; Liu, 
1997). It is important to mention that in addition to compositional differences due to the 
type of salts used, health outcomes may also vary due to differences in protein digestibility 
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resulting from the type of network structure induced by the specific salt used in tofu-
making. 
 
MgCl /CaSO2 4 CaSO4  
Fig. 2. Microstructure of tofu prepared using different salts. 
3.1.4 Other fermented products from soybean 
Soy sauce and soy paste (miso) are fermented soy products that are frequently used as 
condiments and seasoning in foods.  Soy sauce and miso are made by fermenting soybean 
with or without other grains (e.g., wheat, rice, barley) with different types of Aspergillus.   
Soy sauce is obtained in a liquid form whereas miso is a thick paste. These products are 
traditionally used in Asian cuisine but have become a mainstay of many modern diets. 
Tempeh and natto are two other fermented soyfoods but these are less frequently consumed 
outside of Asia. Tempeh is made by fermenting dehulled and cooked soybeans with 
Rhizopus whereas natto is fermented with Baccillus subtilis. The composition of these 
products will again vary depending on the processing conditions used and the amount of 
soybean present in the finished product. Furthermore, microorganisms used during 
fermentation can hydrolyse some phytochemicals such as isoflavones making them more 
bioactive. 
3.1.5 Soy dips/dressings 
There is a wide variety of dips/salad dressings etc. made from soybeans, soy flour, tofu, or 
soy protein isolates available on the market. They contain varying amounts of soy and their 
composition will similarly vary depending on the other ingredients used in the formulation. 
3.1.6 Other soyfoods 
The liquid extract during the preparation of soymilk can be further processed into a variety 
of refrigerated and frozen desserts such as ice cream, soy mousse, and fermented products 
such as soy yoghurt, soy probiotic beverage, and soy cheese, using processes similar to those 
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used in the dairy industry. The composition of these products will vary as a function of the 
ingredients used in processing and the fermentation process including the type of bacteria 
used during fermentation.  
Soybeans can also be roasted in a manner similar to peanuts. The product obtained has a 
nutlike flavour and a crunchy texture which can be consumed as a snack. As these are made 
from intact whole bean, the composition will be similar to that of the starting raw material, 
however, the roasting process can induce changes which may modify digestibility. Roasted 
soybeans can also be ground to obtain roasted soy flour or roasted soynut butter.  
3.2 Major soy ingredients 
3.2.1 Soy oil 
Today soybean oil is one of the world’s leading vegetable oil for human consumption. 
Soybean oil is extracted from the bean after dehulling and flaking using organic solvents. 
The extracted oil is downstream processed to obtain a refined oil. Soybean oil is widely used 
in the manufacture of different foods. It is also frequently used as a salad or cooking oil and 
in the production of shortening, margarines, mayonnaise and salad dressings. By-products 
from the processing of soybean oil are also used to produce mono- and diglycerides and 
lecithin which are commonly used as emulsifying agents in foods. 
3.2.2 Soy flour, soy protein concentrates, isolates and hydrolysates 
Extraction of oil from soybeans leaves behind the soy meal biomass. Significant effort has 
been made in the last few decades to process this meal into value-added products. Defatted 
soy flakes (or flour, grits, meal), soy protein concentrates (SPC) and soy protein isolates (SPI) 
are the three major products available from soy meal. Additionally a full fat or partially 
defatted meal or flour can be obtained from the whole soybean.  
Defatted soy flakes contain approximately 50% protein while, SPC and SPI generally contain 
at least 65% and 90% protein on a dry basis, respectively. Full-fat soy flour may be steamed 
and toasted to inactivate enzymes and enzyme inhibitors or unheated. Unheated, 
undefatted (or defatted) soy flour gives an enzyme active full-fat soy flour which is used in 
the bakery industry to bleach flour.  Mechanically defatted soy meals with different fat 
contents are also available and usually sold in the organic category. Micronized soy 
flour (heat treated with infrared to eliminate anti-nutritional components in soy) are also 
available as whole beans or ground.  
Soy products are widely used in formulated foods, partly because of their nutritional value 
but especially for the functional properties of the protein, which include gelling, foaming 
and emulsification which underlie many food sensory attributes. Other food products likely 
to contain soy ingredients include beverages, nutritional bars, bakery and cereal products, 
soups, meat products, beverages, confectionery, salad dressings and desserts. A growing 
use of soy protein concentrates and isolates is in the preparation of texturized food products 
that are used as meat alternatives or in cereal products. Soy proteins can also be hydrolysed 
enzymatically or chemically to produce hydrolysed vegetable protein (HVP) which is used 
as a flavour enhancer in many foods. 
3.2.3 Other soy ingredients 
In addition to the products listed above, soy dietary fibre, soy hulls, soy isoflavone extracts, 
vitamin E and soy phytosterols are examples of other ingredients from soybean processing 
which are used in nutraceutical products.  
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4. Compositional differences in soy products 
The macro and micro nutrient composition of different soy products will vary markedly 
depending on soybean variety and the attendant biotic and abiotic influences, processing 
condition, other ingredients used in processing and whether the whole soybean or specific 
components are used in product development. Tables 1 to 8 provide detailed lists showing 
some of the compositional differences of a variety of soy products. As can be seen in the 
tables, the composition of protein, isoflavones, mineral, trypsin inhibitors, phytic acid and 
saponins can vary markedly for different soy products. 
Additionally, it is important to note that even within a particular food category the type of 
processing technique and conditions used can impact composition and potential health 
benefits. We have showed in some of our earlier papers that the conditions used for 
processing of soy protein concentrates and isolates (such as particle size, method of 
defatting, process pH) can influence final product composition (Russin et al., 2007; L’hocine 
et al., 2006). Furthermore, Sobral et al. (2010) also reported that methods and conditions of 
preparation and storage of protein samples and mixtures of proteins were factors that 
modified their thermal behavior. In some instances higher denaturation temperatures 
increased thermal stabilization of soybean storage proteins which was attributed to protein-
protein interactions occurring during processing. This increased stabilisation can impact 
digestibility and potentially, bioactivity. 
Conditions used during spray drying can affect product composition. An increase of the 
inlet air temperature during spray drying of fermented soymilk greatly reduced viability 
and isoflavone aglycone content (Telang & Thorat, 2010). Moreover, denaturation of 
proteins during processing further reduced product solubility.   
Processing of soybeans under severe alkaline conditions could lead to the formation of 
lysinoalanine, which can have negative impacts on health and decrease the bioavailability of 
essential amino acids (i.e., lysine). Processing under milder alkaline conditions avoids the 
formation of lysinoalanine and reduces potential negative side effects  (Liener, 1994). 
Additionally, the temperature and time used during the germination of soybeans in the 
production of germinated soybean flour modified the concentrations of bioactive 
compounds (i.e., isoflavones, saponins, trypsin inhibitors and lectins) (Paucar-Menacho et 
al., 2010a). At 25 °C, an increase in germination time decreased the concentration of 
Bowman-Birk inhibitor, lectin and lipoxygenase. Optimal increases in the concentrations of 
isoflavone aglycones (daidzein and genistein) and saponin glycosides were observed with a 
63 h germination time at 30 °C.  In a second study  the authors found that germination of 
soybean for 42 h at 25 °C increased lunasin concentration by 62% and decreased the content 
of lectins by 59% (Paucar-Menacho et al., 2010b). Germination at 25 °C for 42 h resulted in a 
32% increase in the concentration of soy saponins. 
Similarly, fermentation of soymilk using a variety of probiotic lactic acid bacteria (LAB) 
resulted in the production of beta-glucosidase which hydrolyzed isoflavone glucosides to 
the bioactive isoflavone aglycones, genistein and daidzein in the fermented soymilk (Rekha 
& Vijayalakshmi, 2010a, 2011). Furthermore, decreases in phytic acid and increases in 
mineral bioavailability (e.g., calcium) were also observed. Huang et al. (2011) prepared sufu, 
a fermented soybean curd, by ripening salted tofu cubes in Aspergillus oryzae-fermented rice-
soybean koji mash at 25, 35 or 45 °C for a period of 16 days and found that regardless of 
temperature, ripening caused a major reduction in the content of β-glucoside and 
malonylglucoside isoflavones along with a significant increase of aglycone isoflavone 
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Soy product Moisture %
Protein 
% 
Fat  
% 
Carb.4 
% 
Fiber 
 % 
Ash % Reference 
Fresh soybean 68 13 6 11 2 2 
Snyder & Know, 
1987 
Soybean (dry) 7.50-10.1 31.1-36.6 16.3-21.3 6.29 22.0 4.69 Souci et al., 2000 
Soybean (dry) db 39.5-40.1 20.4-21.0 14.7-17.2 21.1-21.7 5.3-5.4
Van der Riet et al., 
1987 
Soybean sprouts  82 8 2 8 1 1 
Snyder & Know, 
1987 
Soy curd 88 6 3 2 0 0.6 
Snyder & Know, 
1987 
Firm tofu 79.3 - 75.5 10.6-14.3     
Shurtleff & 
Aoyagi, 2000 
Edam (cheese) 41.0 28.9 25.0 1.4  3.7 Ono, 2003 
Ganmodoki (tofu 
derivative, td) 
63.5 15.3 17.8 1.6  1.8 Ono, 2003 
Fried bean curd (td) 75.9 10.7 11.3 0.9  1.2 Ono, 2003 
Dried frozen tofu (td) 8.1 49.4 33.2 5.7  3.6 Ono, 2003 
Tempeh unfermented 
soybeans1  
db 48.3 25.7-28.6 2.0-2.8 17.7-19.3 3.0 
Van der Riet et al., 
1987 
Tempeh fermented 
(24h) 
db 48.7-49.7 25.2-27.9 1.9-2.4 18.3-20.2 2.7-2.8
Van der Riet et al., 
1987 
Tempeh fermented 
(48h) 
db 48.6-49-7 25.2-26.3 1.9-2.2 16.1-19.3 2.7 
Van der Riet et al., 
1987 
Tempeh fermented 
(72h) 
db 49.3 22.9-23.8 1.7-2.3 15.3-15.7 3.0 
Van der Riet et al., 
1987 
Tempeh (FWB)2 64 18 4 13  1 
Snyder & Know, 
1987 
Natto (FWB) 2 59 17 10 12 2 3 
Snyder & Know, 
1987 
Hamanatto (FWB) 2 36 26 12 14 3 12 
Snyder & Know, 
1987 
Tempeh Gembus  
(FSP) 3 
81 5 2 11  1 
Snyder & Know, 
1987 
Oncom ampas tahu 
(FSP) 3 
84 4 2 8  2 
Snyder & Know, 
1987 
Soy sauce 72 7 0.5 2 0 18 
Snyder & Know, 
1987 
Fermented soy curd 60 17 14 0.1  9 
Snyder & Know, 
1987 
Soy paste 50 14 5 16 2 15 
Snyder & Know, 
1987 
Ko Chu jang  
(soy paste) 
48 9 4 19 4 20 
Snyder & Know, 
1987 
1Before fermentation; 2 FWB-Fermented whole soybean; 3 FSP-Fermented soy pulp; 4Carbohydrate. 
Table 1. Composition of different soy foods 
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Soy product 
Moisture
%
Protein
%
Fat
%
Carb.1
%
Ash
%
Reference 
Soymilk  94 3 1 1 0.3 
Snyder and 
Know, 1987 
Soymilk  88.7 3.20 1.84 5.76 0.48 
Souci et al., 
2000 
Soy milk (full fat) 
dried 
<10 38 18  <7 
Garcia et 
al.,1997 
Soy milk (low fat) 
dried 
<5 48 9  <5 
Garcia et 
al.,1997 
Soymilk film 9 52 24 12 3 
Snyder and 
Know, 1987 
Soy ice cream   91.12 - 92.45 3.12 – 4.08 1.78 – 1.97 1.89 – 2.66 0.46 – 0.85
Sutar et al., 
2010 
1Carbohydrate 
Table 2. Composition of soymilk and soymilk derived products 
 
Soy product 
Moisture
%
Protein
%
Fat 
%
Carbohydrate
%
Ash 
%
Reference 
Defatted soy meal 53 1 
30
 
Achouri et al., 
2005 
Soya flour (full fat) 
8.94-9.54
35.9-38.8 19.8-22.1
3.10
4.40 
Souci et al., 
2000 
Soyflour (whole) 50   
Hoogenkamp, 
2001 
Soyflour (natural) 40   
Shurtleff & 
Aoyagi, 1983 
Soyflour (full fat) 
dried 
<10
42 21 4.7 
Garcia et 
al.,1997 
Soyflour (defatted) 6-8 52-54 0.5-1.0 30-32 5.0-6.0 Endres, 2001 
Soyflour (defatted) 51   
Shurtleff & 
Aoyagi, 1983 
Soyflour (defatted) 
dried 
6-8
42-52 0.5-1.0 5-6 
Garcia et 
al.,1997 
Toasted soy flour  
5
38 19 
32 5 Snyder & 
Know, 1987 
Soya protein 
concentrate 
4-6
62-69 0.5-1.0 3.8-6.2
Garcia et 
al.,1997 
Soy protein isolate 4-6 86-87 0.5-1.0 3-4 3.8-4.8 Endres, 2001 
Soy protein isolate 
4-6
86-87 0.5-1.0 3.8-4.8
Garcia et 
al.,1997 
1From defatted soybean 
Table 3. Composition of selected soy ingredients 
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Source: Reprinted with permission from Shimoni, 2004.  
(DEN – daidzein; DIN – daidzin; MDN – malonyl daidzin; ADN – acetyl daidzin;  GEN – genistein; 
GIN – genistin; MGN – malonyl genestin; AGN – acetyl genistin; GEIN – glycitein; GIIN – glycitin; 
MGIN – malonyl glycitin; AGIN – acetyl genistin)     
Table 4. Isoflavone content of various soy foods 
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Soy product 
Potassium Phosp.1 Calcium Magn.1 Iron Zinc Magn.1 Sodium Copper 
Ref. 
mg/100g 
Soybean 1693-1739 635-830 187-275 247-282 11.6-11.7 4.5-6.0 2.8-4.1 3.5-9.3 1.7-1.8 2 
Tempeh 
unfermented 
393-525 609-627 192-296 168-172 7.2-8.0 4.5-6.2 3.3-3.7 13.8-16.1 1.6-1.9 2 
Tempeh 
fermented 
soybeans 
(24h) 
222-224 688-731 225-310 193-221 8.7-8.9 5.4-7.1 3.5-4.1 14.2-14.6 1.8-1.9 2 
Tempeh 
fermented 
soybeans 
(48h) 
220-224 731-742 232-333 193-195 9.0 5.5-7.2 3.5-4.1 14.1 1.8-1.9 2 
Tempeh 
fermented 
soybeans 
(72h) 
218-219 734-795 248-318 193-201 8.7-8.8 5.4-7.4 3.6-4.2 13.8-15.1 1.8-1.9 2 
Defatted soy 
four 
2400-2700 700-900 200-300 200-300 10 5 3-4 3-15 1-2 3 
Soy protein 
concentrate 
100-2400 600-900 200-400 300 10-20 5 5 2-1200 1-2 3 
Soy protein 
isolate 
100-1400 500-800 100-200 30-90 10-20 4-9 2 40-1200 1-2 3 
1 Phosp. – phosphorous, Magn. – magnesium, Mang. - manganese; 
2 Van der Riet et al., 1987;  
3 Endres,2001 
Table 5. Mineral content of some soy products  
content. The highest increase in aglycone content and greatest decrease in 
malonylglucosides was observed at 45 °C and increasing ripening time further enhanced the 
changes observed.  
The composition and antioxidant property of tofu is also affected by processing and the type 
of coagulant used (Rekha & Vijayalakshmi, 2010b). Tofu prepared with natural coagulants 
(Citrus limonum, Garcinia indica, Tamarindus indica, Phyllanthus acidus and Passiflora edulis) had 
significantly higher antioxidant activity compared to those prepared with salts. 
Furthermore, higher total crude protein and fat contents were found in some of the tofu 
prepared using the plant based coagulants (G. indica and T. indica).  
Differences were reported in the composition and properties of soy whey (aqueous extract 
of defatted soybean flour) and tofu whey (liquid industrial residue from tofu production) 
(Sobral & Wagner, 2009), two products that may appear to be similar in properties. 
Although both byproducts contain primarily carbohydrates, proteins, non-protein nitrogen 
and salts, tofu whey reportedly had lower amounts of dry matter and proteins, and the 
antitryptic activity was three times lower than in soy whey. Thermal studies conducted 
using differential scanning calorimetry (DSC) of soy whey proteins showed endotherms 
corresponding to lectin and antitryptic factors of Kunitz and Bowman-Birk, whereas the 
thermogram for tofu whey only showed the presence of antitryptic factors. The authors 
attributed these differences to the manufacturing processes used. The extent to which these 
differences can affect health outcomes is unclear. 
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Soy product Trypsin inhibitor 
activity 
mg/g sample 
Reference 
Whole soybean 16.7-27.2 Hafez, 1983 
Whole soybean 48.2 Miyagi et al., 1997 
Raw soy flour 28-32 Rackis et al., 1985 
Raw soy flour 52.1 Anderson et al., 1979 
Toasted soy flour 7.9-9.4 Rackis et al., 1985 
Toasted soy flour 3.2-7.9 Anderson et al., 1979 
Soy protein concentrate 5.4-7.3 Peace et al., 1992 
Soy protein concentrate 6.3-13.9 Anderson et al., 1979 
Soy protein concentrate 4.4-7.3 Peace et al., 1994 
Soy protein isolate 1.2-30.0 Peace et al., 1992 Rackis et al., 
1985 
Soy protein isolate 4.4-11.0 Anderson et al., 1979 
Soy based infant formulas 0.3-2.7 Peace et al., 1992 
Soy tofu 0.6 Doell et al., 1981 
Soy tofu 1.2-3.8 Miyagi et al., 1997 
Soy milk 6.3 Miyagi et al., 1997 
Soy sauce 0.3 Doell et al., 1981 
Soy miso 4.1 Doell et al., 1981 
Soy food fiber 6.47 Anderson et al., 1979 
Chicken analog* 3.63 Anderson et al., 1979 
Ham analog* 5.36 Anderson et al., 1979 
Beef analog* 3.42 Anderson et al., 1979 
Textured soy flour 5.15 Anderson et al., 1979 
* manufactured using soy protein products  
Cited from the following sources: Anderson & Wolf, 1995; Snyder and Know, 1987 (calculated on the 
basis of 1.9TUI = 1 g TI); Gilani et al., 2005. 
 
Table 6. Trypsin inhibitor activity of different soy products 
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Soy product Phytic acid % 
(dry basis) 
Reference 
Soybean 1.12-1.80 Toda et al., 2006 
Soybean 1.00-1.47 Lolas et al., 1976 
Soybean 1.32-2.30 Raboy et al., 1984 
Whole soybean (dry) 1.07 Sutardi & Buclke,1985a 
Soybean, raw 1.41 Sudarmadji & Markakis, 1977 
Soaked (24h) 1.69 Sutardi & Buclke,1985a 
Soybean, soaked 1.43 Sudarmadji & Markakis, 1977 
 Soybean, boiled (5 min) 1.68 Sutardi & Buclke,1985a 
Soybean, boiled 1.23 Sudarmadji & Markakis, 1977 
Soybean soaked (24h) 1.67 Sutardi & Buclke,1985a 
Soybean (dehulled) 1.65 Sutardi& Buclke,1985a 
Soybean (steamed 30 min) 1.48 Sutardi & Buclke,1985a 
Soybean (drained and cooled) 1.47 Sutardi & Buclke,1985a 
Full fat  soy flour 1.51-1.81 Ranhotra et al., 1974 
Defatted soy flour 1.62-1.85 Ranhotra et al, 1974 
Defatted soy flour 1.30-1.63 Schuster & Bodwell, 1980 
Textured soy flour 1.10-2.02 Davies & Reid, 1979 
Textured vegetable protein 0.95-1.63 Harland & Oberleas, 1977 
Concentrate 1.25-2.17 Ranhotra et al, 1974 
Textured concentrate 1.48-1.50 Harland & Oberleas, 1977 
Soy protein isolate 0.97-1.69 Schuster & Bodwell, 1980 
Soy protein isolate 1.61-2.00 Honig et al., 1984 
Spun isolate fiber 1.48 O’Neill et al., 1980 
Soymilk 1.68 Omosaiye & Cheryan, 1979 
Soymilk 1.83 Beleia et al., 1990 
Tofu 1.5-2.5 Van der Riet et al., 1989 
Tofu 1.96-2.88 Schaefer & Love, 1992 
Okara (residue from soymilk) 0.5-1.2 Van der Riet et al., 1989 
Tempeh 0.69-0.73 Sutardi & Buckle, 1985b 
Tempeh unfermented soybeans 
(before fermentation) 
1.0-1.2 Van der Riest et al., 1987 
Tempeh fermented soybeans (24h) 0.3-0.6 Van der Riest et al., 1987 
Tempeh fermented soybeans (48h) 0.2-0.4 Van der Riest et al., 1987 
Tempeh fermented soybeans (72h) 0.1-0.2 Van der Riest et al., 1987 
Tempeh (fresh)* 0.68-0.75 Sutardi & Buclke,1985a 
Tempeh 0.96 Sudarmadji & Markakis, 1977 
Fried fresh Tempeh* 0.35-0.38 Sutardi & Buclke,1985a 
Tempeh stored 2wk@5°C* 0.18-0.19 Sutardi & Buclke,1985a 
Fried stored tempeh* 0.09-0.10 Sutardi & Buclke,1985a 
* Different types of inoculation used in production 
Data taken from the following source: Anderson & Wolf, 1995 
Table 7. Phytic acid content of different soy products 
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Soy product Saponin content 
%
Reference
Soybean 0.44-0.49 Berhow et al., 2006 
Soybean 0.47 Ireland et al., 1986 
Soybean 0.225-0.298 Kitagawa et al., 1984 
Soybean 5.1 Fenwick & Oakenfull, 1981 
Soybean 3.9 Fenwick & Oakenfull, 1983 
Soybean 0.46-0.50 Gestetner et al.,1966 
Soybean 5.6 Fenwick & Oakenfull, 1981 
Toasted, defatted soy flour 0.67 Ireland et al., 1986 
Defatted soy flour 2.0 Fenwick & Oakenfull, 1981 
Defatted soy flour 0.35 Curl et al.,1985
Defatted soy flour 2.2-2.5 Fenwick & Oakenfull, 1981 
Commercial soy flour 0.46 Price et al.,1985
Soya hulls 2.0 Fenwick & Oakenfull, 1981 
Full fat, enzyme active soy flour 0.43 Ireland et al., 1986 
Full fat, heat treated soy flour 0.49 Ireland et al., 1986 
Soya protein isolate 0.76 Ireland et al., 1986 
Soy protein isolate : Promine D* 0.3 Fenwick & Oakenfull, 1981 
Soy protein isolate : GL-750* 0.8 Fenwick & Oakenfull, 1981 
Soy protein isolate : Maxten C* 1.9 Fenwick & Oakenfull, 1981 
Soy protein isolate : Maxten E* 2.5 Fenwick & Oakenfull, 1981 
Soymilk  0.026 Ireland et al., 1986 
Soymilk  0.022 Ireland et al., 1986 
Soymilk  0.39 Kitagawa et al., 1984 
Yuba (dried soymilk film) 0.41 Kitagawa et al., 1984 
Okara (residue of soymilk) 0.10 Kitagawa et al., 1984 
Tofu 2.1 Fenwick & Oakenfull, 1981 
Tofu 0.30-0.33 Kitagawa et al., 1984 
Miso 0.15 Kitagawa et al., 1984 
Natto 0.25 Kitagawa et al., 1984 
Tonyu (soya milk) 0.047 Kitagawa et al., 1984 
*trademark 
Table 8. Saponin content of different soy products 
In addition to processing, various plant breeding techniques have been used to modify the 
composition of soybeans for different food applications (Esteves et al., 2010, Brune et al., 
2010). Thus depending on the type of variety used, compositional differences can be 
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expected in macro and micro components (i.e., protein, indispensable, dispensable and total 
amino acid, lunasin, isoflavones, phytic acid, oxalate and trypsin inhibitors as well as 
mineral content). The biological activity of soybean products will, therefore, not only 
depend on the processing technique used but the variety of soybean used.  
5. Soyfoods and health claims 
An important factor that may contribute to inconsistencies in the evidence of the health 
benefit of soy may be related to the type of material used for clinical studies. Reinwald et al. 
(2010) argue the possibility that whole soy may have a more unique effect on health than a 
select soy component.  
Differences in health outcomes related to soy and soy component consumption could be due 
to varietal and compositional differences, the impact of processing, additive effects of 
various components (i.e., the whole is greater than the sum of the parts) as well as age and 
health status. Furthermore, some have argued that the presence or absence of specific gut 
microflora could also contribute to health outcomes (Patisaul & Jefferson, 2010) as 
microorganisms may play a critical role in converting physiologically inactive 
phytochemicals to the bioactive form.  
As an example, Reinwald and Weaver (2010) have reported that whereas epidemiological 
studies in Asia evaluating diets containing traditional whole soyfoods showed a positive 
association with bone mineral density and fracture protection, smaller scale intervention 
studies in Western nations mainly using isolated soy protein (SP) and purified or 
concentrated soy isoflavones (SI) rather than whole soyfoods have produced inconsistent 
results.  
Similarly, Lagari and Levis (2010) found that clinical trials are conflictive regarding the 
effects of phytoestrogens on bone mineral density and bone turnover markers in 
premenopausal and postmenopausal women and argue that much of the controversy lies in 
differences in study design, reporting of results, participants' age and menopausal status, 
and type and dose of phytoestrogen used. 
In Canada, where a health claim for soy has not yet been approved, the ministry 
responsible for health (Health Canada) requires the following evidence to substantiate 
health claims: 
1. Causality – Evidence of high quality and quantity of original research in humans based 
on randomized controlled intervention and / or prospective observational studies are 
mandatory to substantiate the health claim of food or food constituents with high level 
of certainty (statistical significance achieved at p≤0.05) and the relationship between the 
amount of food and the health effect.  
2. Generalizability - The claimed effect of the food of food constituent is biologically / 
physiologically relevant and expected to benefit the health of the target population, 
appropriate and validated surrogate marker must be used to ensure the biological 
relevance and it should be part of the causal pathway between the food and the health 
outcome.   
3. Quality assurance - The food is produced according to quality standards and 
consistently meets predefined specifications.  
4. Safety - The subject of a health claim application must be for a food approved for safe 
use; or, if a novel food is the subject of the health claim, a novel food application must 
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be completed and submitted to Health Canada preceding or concurrent with this 
application. The adverse effects related to food intake observed in human studies 
should be addressed and must provide risk management strategies to overcome the 
adverse effects and or restriction on use of food.   
As there is a wide variety of soy products available on the market, the specific type used for 
clinical studies can impact results.  
A major challenge for health claim support studies is the lack of standardized materials and 
controls for clinical studies as well as the use of appropriate clinical outcomes and surrogate 
endpoints for different disease risks. Furthermore, very few studies have been conducted to 
understand what happens to soyfoods and soy components in the gastrointestinal tract and 
the specific events that occur at the mucosal barrier and how these events influence 
absorption, distribution, metabolism and excretion. The gastrointestinal mucosa is an 
interesting and complex system that acts as a barrier between the body and the lumenal 
environment and is selective in that it allows the transfer of selected nutrients across the 
epithelium while excluding perceived harmful components in the bolus. This complex 
interplay between bioactives and the intestinal mucosa also needs to be carefully 
documented to support any eventual health claim. Matrix interactions can influence the 
bioactivity of the components of interest and the functional properties of the matrix. 
Furthermore, for double blind placebo controlled studies which are the gold standard in 
clinical studies, the effect of the matrices used in the clinical trials need to be carefully 
evaluated. 
As policy makers, food regulators, industry and consumers in other jurisdictions demand 
more evidence to support current and future health claims, some question of interest that 
remain include the following: 
 What is the relationship reported between the exposure to soy and specific health 
effects from both observational and intervention studies that meet selection criteria?  
 Can a clear distinction be made between the effect of soy protein alone and soy protein 
within a matrix (e.g., whole soybean foods and foods made from soy protein 
ingredients)?  
 What is the efficacy of soy proteins in which isoflavones have been removed versus soy 
proteins that contain isoflavones in respect to relationship with cardiovascular disease 
risk reduction and other health claims?  
 How are breakdown products absorbed in the gastrointestinal tract and how do they 
exert physiological effects in the body?  
 How do matrix effects influence adsorption, digestion, metabolism and excretion?  
 What is the impact of processing on the efficacy of soy protein and the bioactivity of 
materials used in clinical trials?  
 What are the ideal samples and controls that should be used in clinical trial studies for 
specific clinical outcomes and what surrogate endpoints should be used?  
 What is the feasibility for consuming recommended intake levels for health claims 
especially in populations that do not consume soy frequently (e.g., is the consumption 
of 20-25 g of soy protein a day feasible?)?  
 What is the documented effect of anti-nutritional factors such as trypsin inhibitors, 
phytates, lectins and lysinoalanine and the extent of heat resistance of trypsin inhibitors 
found in soybeans?  
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6. Conclusion 
Soy protein has officially been approved in several countries as a “functional food”, making 
it one of the most valuable vegetable proteins in the world today.  As concerns about health, 
climate change and the impacts of agricultural practices increase, assurance of a diversified 
sustainable source of nutrition that provides proven health benefits will become 
increasingly important. Soybeans can contribute to this nutrient biodiversity in an 
instrumental way. In crop production and rotation, soybeans play a crucial role in nitrogen 
fixation making them an important component of agricultural sustainability. Furthermore, 
soy proteins have excellent functional properties that can be exploited in various food 
applications. Processing technologies are continually being investigated for soy protein 
fractionation which will allow modifications in protein profile and which could dramatically 
improve suitability of soy protein products for targeted food, nutraceutical and industrial 
applications (e.g., enriched 11S, 7S, or 2S soy protein extracts). Breeding efforts to remove or 
enhance mico nutrients and other bioactive components are also likely to have an impact on 
improving health outcomes. To support health claims and enhance the benefits of 
consumption, constant evaluation of the totality of the body of knowledge in regards to 
potential health benefits and well designed experimental studies using well characterized 
materials will, therefore, be needed.  
7. References  
Achouri, A., Boye, J.I., Belanger, D. 2005. Soybean isoflavones: Efficacy of extraction 
conditions and effect of food type on extractability. Food Research International, 38, 
pp. 1199-1204.  
Anderson, R.L., Rachkis, J.J., Tallent, W.H. 1979. Biologically active substances in soy 
products, In Soy Protein and Human Nutrition, Editors: Wilcke H.L., Hopkins D.T. 
Waggle D.H., eds. Academic Press, New York. 
Anderson, R.L., Wolf, W.J. 1995. Overview of soy processing and products: Compositional 
changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to 
soybean processing. Journal of Nutrition, 125, pp. 581S-588S. 
Beleia, A., Ida, E.I., Lethi, T.T. 1990. Phosphorus and pytic acid distribution during soy 
milk processing. Brazilian Archives of Biology and Tecnology (Arq.Biol. Technol), 33, 
pp. 623-629. 
Berhow, M.A., Bin Kong, S., Vermillion, K.E., Duval, M.S. 2006. Complete quantification of 
group A and group B soyasaponins in soybeans. Journal of Agricultural and Food 
Chemistry, 54 (6), pp. 2035-2044. 
Bruckert, E., Rosenbaum, D. 2011. Lowering LDL-cholesterol through diet: Potential role in 
the statin era. Current Opinion in Lipidology, 22(1), 43, pp. 48-64.  
Brune, M.F.S.S, Pinto, M.S., Peluzio, M.C.G., Moreira, M.A., de Barros, E.G. 2010. 
Biochemical and nutritional evaluation of a soybean line lacking the kunitz trypsin 
inhibitor and lectins. Ciencia e Tecnologia de Alimentos, 30(3), pp. 657-63.  
Chiang, W. D., Tsou, M. J., Tsai, Z. Y., Tsai, T. C. 2006. Angiotensin I-converting enzyme 
inhibitor derived from soy protein hydrolysate and produced by using membrane 
reactor. Food Chemistry, 98, pp. 725-732.  
www.intechopen.com
 
Assessing Compositional Differences in Soy Products and Impacts on Health Claims 
 
471 
Curl, C. L., Price, K.R., Fenwick, G.R. 1985. The quantitative estimation of saponin in pea 
(pisum sativum L) and soya (Glycine max). Food Chemistry, 18, pp. 241-250. 
Davies, N.T., Reid H. 1979. An evaluation of the phytate, zinc, copper, ion and 
manganese contents of, and Zn availability from, soya-based textyured-
vegetable-protein meat-substitutes or meat-extenders. British Journal of 
Nutrition, 41, pp. 579-589. 
Endres, J.E. 2001. Soy protein products – Characteristics, nutritional aspects, and utilization, 
revised and expanded Edition, a publication of AOCS press, P.O. Box 3489 
Champain, IL. 61826-3489 USA - ISBN 1-893997-27-8. 
Erdos, E. G. 1975. Angiotensin I-converting enzyme. Circulation Research, 36, pp. 247-
255. 
Esteves, E.A., Martino, H.S.D., Oliveira, F.C.E., Bressan, J., Costa, N.M.B. 2010. Chemical 
composition of a soybean cultivar lacking lipoxygenases (LOX2 and LOX3). Food 
Chemistry, 122(1), pp. 238-242.  
Fenwick D.E., Oakenfull, D. 1981. Saponin content of soya beans and some commercial soya 
bean products. Journal of the Science of Food and Agriculture, 32, pp. 273-278. 
Fenwick, D.E., Oakenfull, D. 1983. Saponin content of food plants and some prepared foods, 
Journal of the Science of Food and Agriculture, 34, pp. 186-191. 
Garcia, M.C., Torre, M., Marina, M.L., Laorda, F. 1997. Composition and characterization of 
soyabean and related products, Critical Reviews in Food Science and Nutrition, 37(4), 
pp. 361-391. 
Gestetner, B., Birk, Y., Bondi, A., Tencer, Y. 1966. Soya bean saponins – VII. A method for the 
determination of sapogenin and saponin contents in soya beans. Phytochemistry, 5, 
pp. 803-806. 
Gilani, G.S, Cockell, K.A., Sepehr, E. 2005. Special guest editor section: Effets of 
antinutritional factors on protein digestibility and amino acid availability in 
foods. Journal of the Association of Analytical Chemists International, 88(3), 
967-987. 
Harland, B.F., Oberleas, D. 1977. A modified method for phytate analysis using an ion-
exchange procedure: application to textured vegetable proteins. Cereal Chemistry, 
54, pp. 827-832. 
Harlanda, J.I., Haffnerb, T.A. 2008. Systematic review, meta-analysis and regression of 
randomised controlled trials reporting an association between an intake of circa 25g 
soy protein perd ay and blood cholesterol. Atherosclerosis, 200, pp. 13-27.  
Hartmann, R., Meisel, H. 2007. Food-derived peptides with biological activity: from research 
to food applications. Current Opinion in Biotechnology, pp. 18, 1-7.  
Hiwatashi, K., Shirakawa, H., Hori, K., Yoshiki, Y., Suzuki, N., Hokari, M., Komai, M., 
Takahashi, S. 2010. Reduction of blood pressure by soybean saponins, renin 
inhibitors from soybean, in spontaneously hypertensive rats. Bioscience, 
Biotechnology and Biochemistry, 74(11), pp. 2310-2312.  
Hogervorst, E., Mursjid, F., Priandini, D., Setyawan, H., Ismael, R.I., Bandelow, S., Rahardjo, 
T.B. 2011. Soy consumption may be associated with better recall in younger, but not 
in older, rural indonesian elderly. Brain Research, 1379, pp. 206-212. 
www.intechopen.com
 
Soybean and Nutrition 
 
472 
Honig, D.H., Wolf, W.J., Rackis, J.J. 1984. Phytic acid and phosphorus content of various 
soybean protein fractions. Cereal Chemistry, 61, pp. 523-526. 
Hoogenkamp H.W. 2001 Soy protein & meat formulations, In Lifestyle Marketing Dynamics 
Coupled With Modern Processing Techniques and Old Time Favorites, published by 
Protein Technologies International – A DuPont Business P.O. Box 88940, St Louis, 
MO 63188. 
Huang, Y., Lu, T., Chou, C. 2011. Ripening temperature affects the content and distribution 
of isoflavones in sufu, a fermented soybean curd. International Journal of Food Science 
and Technology, 46(2), pp. 257-262.  
Ireland, P.A., Dziedzic, S.Z., Kearsley, M.W. 1986. Saponin content of soya and some 
commercial soya products by means of Hight-performance liquid 
chromatography of sapogenins. Journal of the Science of Food and Agriculture, 37, 
pp. 694-698. 
Jenkins, D.J.A., Mirrahimi, A., Srichaikul, K., Berryman, C.E., Wang, L., Carleton, A., 
Abdulnour, S., Sievenpiper, J.L., Kendall, C.W.C., Kris-Etherton, P.M. 2010. Soy 
protein reduces serum cholesterol by both intrinsic and food displacement 
mechanisms. Journal of Nutrition, 140(12), pp. 2302S-2311S.  
Kang, J., Badger, T.M., Ronis, M.J.J., Wu, X. 2010a. Non-isoflavone phytochemicals in soy 
and their health effects. Journal of Agricultural and Food Chemistry, 58(14), pp. 8119-
8133.  
Kang, X., Zhang, Q., Wang, S., Huang, X., Jin, S. 2010b. Effect of soy isoflavones on breast 
cancer recurrence and death for patients receiving adjuvant endocrine therapy. 
Canadian Medical Association Journal, 182(17), pp. 1857-1862.  
Kitagawa, I., Yoshikawa, M., Hayashi, T., Taniyama, T. 1984. Quantitative determination of 
soyasaponins in soybeans of various origins and soybean products by means of 
high performance liquid chromatography. Yakugaku Zasshi, 104, 275-279. 
Kuba, M., Tanaka, K., Tawata, S., Takeda, Y., Yasuda, M. 2003. Angiotensin I-converting 
enzyme inhibitory peptides isolated from tufuyo fermented soybean food. 
Bioscience Biotechnology and Biochemistry, 67, pp. 1278-1283. 
Lagari, V.S., Levis, S. 2010. Phytoestrogens and bone health. Current Opinion in 
Endocrinology. Diabetes and Obesity, 17(6), pp. 546-553.  
L'Hocine, L., Boye, J.I., Arcand, Y. 2006. Composition and functional properties of soy 
protein isolates prepared using alternative defatting and extraction procedures. 
Journal of Food Science, 71(3), pp. C137-145. 
Liener, I.E. 1994. Implications of antinutritional components in soybean foods. Critical 
Reviews in Food Science and Nutrition, 34(1), pp. 31-67.  
Liener, I.E. 1996. Effects of processing on antinutritional factors in legumes: The soybean 
case. Archivos latinoamericanos de nutricio ́n, 44(4 Suppl 1), pp. 48S-54S.  
Liu, K. 1997. Soybeans: Chemistry, Technology and Utilization. Aspen Publishers, USA 
Originally published by Chapman and Hall, New York, USA. 
Lolas, G.M., Palamidis, N., Markakis, P. 1976. The phytic acid total phosphorus relationship 
in barley, oats, soybeans and wheat. Cereal Chemistry, 53, pp. 867-871. 
Merritt, J. C. 2004. Metabolic syndrome: soybean foods and serum lipids. Jouranl of the 
National Medical Association, 96, pp. 1032–1041.  
www.intechopen.com
 
Assessing Compositional Differences in Soy Products and Impacts on Health Claims 
 
473 
Messina, M. 2010. Insights gained from 20 years of soy research. Journal of Nutrition, 140(12), 
pp. 2289S-2295S.  
Miyagi, Y., Shinjo, S., Nishida, R., Miyagi, C., Takamatsu, K., Yamamoto, T., Yamamoto, S. 
1997. Journal of Nutritional Science and Vitaminology, 43, pp. 575-580. 
Nilavsen, K., Meinertz, H. 1998. Variable response to dietary soy protein in healthy 
normolipidemic men. American Journal of Clinical Nutrition, 68, pp. 1380S-1384S.  
O’Neill, J.K., Sargent, M., Trimble, M.L. 1980. Determination of phytate in foods by 
phophorus 31 Fournier transfrom nuclear magnetic resonance spectrometry. 
Analytical Chemistry, 52, pp. 1288-1291. 
Ogborn, M.R., Nitschmann, E., Bankovic-Calic, N., Weiler, H.A., Aukema, H.M. 2010. 
Dietary soy protein benefit in experimental kidney disease is preserved after 
isoflavone depletion of diet. Experimental Biology and Medicine. 235(11), pp. 1315-
1320.  
Omosaiye, O., Cheryan, M. 1979. Low-phytate, full fat soy protein product by ultrafiltration 
of aqueous extracts of whole soybeans. Cereal Chemistry, 56, pp. 58-62. 
Ono T. 2003. Soy (soya) Cheeses In: Encyclopedia of Food Sciences and Nutrition, Second 
edition, Editors: Caballero B, Trugo L. C. Finglas P. M., Acadamic Press – ISBN 0-
12-227055-X, pp. 5398-5402. 
Onuegbu, A.J., Olisekodiaka, J.M., Onibon, M.O., Adesiyan, A.A., Igbeneghu, C.A. 2011. 
Consumption of soymilk lowers atherogenic lipid fraction in healthy individuals. 
Journal of Medicinal Food, 14(3), pp. 257-260.  
Patisaul, H.B., Jefferson, W. 2010. The pros and cons of phytoestrogens. Frontiers in 
Neuroendocrinology, 31(4), pp. 400-419.  
Paucar-Menacho, L.M., Berhow, M.A., Mandarino, J.M.G., Chang, Y.K., Mejia, E.G.D. 
2010a. Effect of time and temperature on bioactive compounds in germinated 
Brazilian soybean cultivar BRS 258. Food Research International, 43(7), pp. 1856-
1865.  
Paucar-Menacho, L.M., Berhow, M.A., Mandarino, J.M.G., de Mejia, E.G., Chang, Y.K. 
2010b. Optimisation of germination time and temperature on the concentration of 
bioactive compounds in Brazilian soybean cultivar BRS 133 using response surface 
methodology. Food Chemistry, 119(2), pp. 636-642.  
Peace, R.W., Sarwar, G., Touchburn, S.P. 1994. Trypsin inhibitor levels in soy-based infant 
formulas and commercial soy protein isolates and concentrates. Food Research 
International, 25, 137-141. 
Potter, S.M., Baum, J.A, Teng, H., Stillman, R.J., Shay, N.F, Erdman J.W. 1998. Soy protein 
and isoflavones. American Journal of Clinical Nutrition, 68, pp. 1375S-1379S.  
Price, K.R., Griffiths, N.M., Curl, C.L., Fenwick, G.R 1985. Undesirable sensory propeties of 
the dried pea. Food Chemistry, 25, pp. 105-115. 
Raboy, V., Dickinson, D.B., Below, F.E. 1984. Variation in seed total phosphorus, phytic acid, 
zinc, calcium, magnesium and protein among lines of Glycine max and G. soja. 
Crop Science, 24, pp. 431-434. 
Ranhotra, G.S., Loewe, R.J., Puyat, L.V. 1974. Phytic acid in soy and its hydrolysis during 
breadmaking. Journal of Food Science, 39, pp. 1023-1025. 
www.intechopen.com
 
Soybean and Nutrition 
 
474 
Reinwald, S., Akabas, S.R., Weaver, C.M. 2010. Whole versus the piecemeal approach to 
evaluating soy. Journal of Nutrition, 140(12), pp. 2335S-2343S.  
Reinwald, S., Weaver, C.M. 2010. Soy components vs. whole soy: Are we betting our bones 
on a long shot? Journal of Nutrition, 140(12), pp. 2312S-2337S.  
Rekha, C.R., Vijayalakshmi, G. 2010a. Bioconversion of isoflavone glycosides to aglycones, 
mineral bioavailability and vitamin B complex in fermented soymilk by probiotic 
bacteria and yeast. Journal of Applied Microbiology, 109(4), pp. 1198-1208.  
Rekha, C.R., Vijayalakshmi, G. 2010b. Influence of natural coagulants on isoflavones 
and antioxidant activity of tofu. Journal of Food Science and Technology, 47(4), pp. 
387-393.  
Rekha, C.R., Vijayalakshmi, G. 2011. Isoflavone phytoestrogens in soymilk fermented with 
β-glucosidase producing probiotic lactic acid bacteria. International Journal of Food 
Science and Nutrition, 62(2), pp. 111-120.  
Russin, T.A., Arcand, Y., Boye, J.I. 2007. Particle size effect on soy protein isolate extraction. 
Journal of Food Processing and Preservation, 31(3), pp. 308-319. 
Sacks, F. M, Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., Winston, M. 2006. 
Soy protein, isoflavones, and cardiovascular health: An American Heart 
Association Science Advisory for Professionals from the Nutrition Committee. 
Circulation, 113, pp. 1034 – 1044.  
Sakač, M., Čanadanovič-Brunet, J., Mišan, A., Tumbas, V., Medič, D. 2010. Antioxidant 
activity of phytic acid in lipid model system. Food Technology and Biotechnology, 
48(4), pp. 524-529.  
Schaefer, M.J., Love, J. 1992. Relationship between soybean components and tofu texture. 
Journal of Food Quality, 15, pp. 53-66. 
Schuster, E.M., Bodwell, C.E. 1980. Phytic acid content of thirty-two commercial soy 
products. Federation Proceedings, 39, pp. 659(abs). 
Shimoni, E. 2004. Stability and shelf life of bioactive compound during food processing and 
storage : Soy isoflavones. Journal of Food Science: Concise Reviews in Food Science, 
69(6), pp. R160-R166. 
Shurtleff, W., Aoyagi, A. 1983. The book of tofu, Protein source of the future …now!, 
Completed & Unabridged, vol I, Ten Speed Press - A Soyfoods Center book   ISBN 
0-89815-095-7. 
Shurtleff, W., Aoyagi, A. 2000. Tofu & soymilk Production, The book of tofu, volume II, A 
Craft and Technical Manual, Soyfoods Center   ISBN 1-928914-04-1. 
Snyder, H.E., Know, T.W. 1987. Soybean Utilization. Van Nostrand Rienhold Company 
Inc, 115th Fifth Avenue New York, New York, 10003 , an AVI book  - ISBN 0-
442-28216-6. 
Sobral, P.A., Palazolo, G.G., Wagner, J.R. 2010. Thermal behavior of soy protein fractions 
depending on their preparation methods, individual interactions, and storage 
conditions. Journal of Agricultural and Food Chemistry, 58(18), pp. 10092-10100.  
Sobral, P.A., Wagner, J.R. 2009. Relationship between the composition and antitryptic 
activity of soy and tofu wheys and thermal behavior of their isolated protein. 
Informacion Tecnologica, 20(5), pp. 65-74.  
www.intechopen.com
 
Assessing Compositional Differences in Soy Products and Impacts on Health Claims 
 
475 
Souci F.W., Fachman W., Kaut H. 2000. Food composition and nutrition tables, 6th revised 
and completed edition, Medphram Scientigfic publishers, CRC press. 
Sudarmadji, S., Markakis, P. 1977. The phytate and phytase of soybean tempeh.  Journal of 
the Science of Food and Agriculture, 28, pp. 381-383. 
Sutar, N., Sutar, P.P., Singh, G. 2010. Evaluation of different soybean varieties for 
manufacture soy ice cream. International Journal of Dairy Technology, 63(1), pp. 
136-142. 
Sutardi, Buckle, K.A. 1985a. Reduction in phytic acid levels in soybeans during tempeh 
production, storage and frying. Journal of Food Science, 50, pp. 260-263. 
Sutardi , Buckle, K.A. 1985b. Phytic acid changes in soybeans fermented by traditional 
inoculum and six strains of Rhizopus oligosporus. Journal of Applied Bacteriology, 
58, pp. 539-543. 
Taku, K., Lin, N., Cai, D., Hu, J., Zhao, X., Zhang, Y., Wang, P., Melby, M.K., Hooper, L., 
Kurzer, M.S., Mizuno, S., Ishimi, Y., Watanabe, S. 2010. Effects of soy isoflavone 
extract supplements on blood pressure in adult humans: Systematic review and 
meta-analysis of randomized placebo-controlled trials. Journal of Hypertension, 
28(10), pp. 1971-1982.  
Taku, K., Umegaki, K., Ishimi, Y., Watanabe, S. 2008. Effects of extracted soy isoflavones 
alone on blood total and LDL cholesterol: Meta-analysis of randomized controlled 
trials. Journal of Therapeutics and Clinical Risk Management, 5, pp. 1097-1103.  
Telang, A.M., Thorat, B.N. 2010. Optimization of process parameters for spray drying of 
fermented soy milk. Drying Technology, 28(12), pp. 1445-1456.  
Tian, J., Zhao, S., Zhai, B., Xu, L. 2010. Biotransformation of group B soybean saponins. 2010 
4th International Conference on Bioinformatics and Biomedical Engineering, 
iCBBE. ISBN 978-1-4244-4712-1, pp. 1-3. 
Toda, K., Takahashi, K., Ono, T., Kitamura, K., Nakamura, T. 2006. Variation in phytic acid 
content of soybeans and its effect on consistency of tofu made from soybean 
varieties with high protein content. Journal of the Science of Food and Agriculture, 86, 
pp. 212-219. 
Tsai, C., Chen, Y., Chien, Y., Huang, W., Lin, S. 2010. Effect of soy saponin on the 
growth of human colon cancer cells. World Journal of Gastroenterology, 16(27), 
pp. 3371-3376.  
Van der Riet, W.B., Wight A. W., Cilliers J.J.L., Datel J.M. 1987. Food chemical analysis 
of tempeh prepared from South African-grown soybeans. Food Chemistry, 25, 
pp. 197-206. 
Van der Riet, W.B., Wight A. W., Cilliers J.J.L., Datel J.M. 1989. Food chemical investigation 
of tofu and its byproduct okara. Food Chemistry, 34, pp. 193-202. 
Wang, H.L., Swain, E.W., Kwolek, W.F. 1983. Effect of soybean varieties on the yield and 
quality of tofu. Cereal Chemistry, 60, pp. 245-248. 
Wu, J., Ding, X. 2002. Characterization of inhibition and stability of soy-protein-derived 
angiotensin I-converting enzyme inhibitory peptides. Food Research International, 35, 
pp. 367-375. 
www.intechopen.com
 
Soybean and Nutrition 
 
476 
Yang, H.Y.T., Erdos, E.G., Levin, Y.A. 1970. A dipeptidyl carboxypeptidase that 
converts angiotensin I and inactivates bradykinin. Biochimica et Biophysica Acta, 
214, pp. 374-376. 
Yang, H.Y., Yang, S.C., Chen, S.T., Chen, J.R. 2008. Soy protein hydrolysate ameliorates 
cardiovascular remodeling in rats with L-NAME-induced hypertension. Journal of 
Nutritional Biochemistry, 19, pp. 833-839. 
Zhuo, X.G, Melby, M. K., Watanabe, S. 2004. Soy isoflavone intake lowers serum LDL 
cholesterol: A meta-analysis of 8 randomized controlled trials in humans. Journal of 
Nutrition, 134, pp. 2395-2400.  
www.intechopen.com
Soybean and Nutrition
Edited by Prof. Hany El-Shemy
ISBN 978-953-307-536-5
Hard cover, 476 pages
Publisher InTech
Published online 12, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Worldwide, soybean seed proteins represent a major source of amino acids for human and animal nutrition.
Soybean seeds are an important and economical source of protein in the diet of many developed and
developing countries. Soy is a complete protein and soy-foods are rich in vitamins and minerals. Soybean
protein provides all the essential amino acids in the amounts needed for human health. Recent research
suggests that soy may also lower risk of prostate, colon and breast cancers as well as osteoporosis and other
bone health problems and alleviate hot flashes associated with menopause. This volume is expected to be
useful for student, researchers and public who are interested in soybean.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Joyce Boye and Sabine Ribe ́reau (2011). Assessing Compositional Differences in Soy Products and Impacts
on Health Claims, Soybean and Nutrition, Prof. Hany El-Shemy (Ed.), ISBN: 978-953-307-536-5, InTech,
Available from: http://www.intechopen.com/books/soybean-and-nutrition/assessing-compositional-differences-
in-soy-products-and-impacts-on-health-claims
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
